EUCTR2007-003307-13-FI进行中（未招募）不适用
A Phase 2a, Open-label, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intranasal Clonazepam in Adult Subjects with Epileptic Seizures
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Diagnosis of refractory epilepsy (a failure of at least 2 antiepileptic drugs to control seizures) for at least 2 months prior to study start. Identifiable partial or generalized seizure types are allowed provided they have a clear or reproducible EEG component.
- •2. Epilepsy subjects with a history of predictable daily seizure patterns. Subjects must average at least 7 seizures per week, with no more than 2 seizure-free days per week.
- •3. No nasal conditions that would preclude the use of an intranasal product.
- •4. Adult male and female subjects ages 18 to 65 years, inclusive.
- •5. Body Mass Index (BMI) less than 35 kg/m2.
- •6. Body weight no less than 100 lbs/45.5 kgs.
- •7. Has maintained stable doses of concomitant AEDs for at least 1 month prior to study entry (Day -1).
- •8. Willingness and ability to maintain a stable dose of current medications used to treat epilepsy (or other conditions) for the duration of the study
- •9. Good general health as determined by physical and neurological examination, medical history, clinical laboratory findings, and ECG at screening, as determined by the investigator.
- •10. Consent to use a medically acceptable method of contraception throughout the entire study period and for one week after the study is completed. Medically acceptable methods of contraception that may be used by the subject and/or the partner include abstinence, hormonal contraceptives, diaphragm and spermicide, intrauterine device (IUD), condom and vaginal spermicide, surgical sterilization, post-menopausal, and vasectomy (>6 months prior to Baseline).
- •11. Negative drug and alcohol screens at screening and baseline (Day -1). Subjects who test positive for barbiturates and benzodiazepines will not be excluded from the study, provided these drugs have been prescribed as AEDs for treatment of their epilepsy or anxiety.
- •12. No clinically significant hematological abnormalities in laboratory screening.
- •13. Ability for subject to read, understand, and provide written informed consent before enrolling in the study, and willingness to comply with all study procedures.
- •14. Agreement to remain in the study facility for the duration of the study (up to 9 calendar days).
- •15. Negative pregnancy test for all females at screening and baseline (Day -1).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subjects with a clinically significant unstable medical abnormality, chronic disease, or history or presence of significant hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, psychiatric, or metabolic disease or any other abnormality (other than epilepsy) that could interfere with evaluation of the study drug.
- •2. Subjects in the EMU for pre-surgical evaluation.
- •3. Biochemical evidence of significant liver disease at screening.
- •4. Subjects who have experienced psychogenic non-epileptic seizures within the last 2 years.
- •5. Vagus nerve stimulator (VNS) implant within 3 months prior to enrollment (Day -1) or VNS setting adjusted within 30 days prior to enrollment.
- •6. Subjects who have experienced status epilepticus within the last 12 months.
- •7. Acute narrow angle glaucoma.
- •8. Subjects with any severe drug allergy, history of allergic or severe adverse drug reactions, or intolerance to clonazepam, other benzodiazepines, or the excipients used in the intranasal spray.
- •9. Subjects taking more than three concurrent AEDs (may be included after consultation with the medical monitor).
- •10. Subjects currently or regularly taking clonazepam
- •11. Use of an epilepsy rescue medication within five drug half-lives of clinic entry (Day -1).
- •12. Use of an OTC or prescription intranasal product within five drug half-lives of clinic entry (Day -1).
- •13. Subjects who require the use of a rescue medication more than twice per week.
- •14. Subjects with clinically significant illness (other than refractory epilepsy) within 30 days of screening, as determined by the investigator.
- •15. Subjects with a clinically significant abnormal finding (other than epilepsy) on physical or neurological examination, ECG, or clinical laboratory tests, as determined by the investigator at screening.
- •16. Subjects with a history of alcohol or drug abuse that in the investigator’s judgment will affect the subject’s safety and/or ability to complete the study.
- •17. Females who are pregnant, breastfeeding, or lactating.
- •18. Subjects who self-report ingestion of alcohol within 48 hours prior to dosing through completion of the study.
- •19. Subjects who used any other investigational drug or device within 30 days or five half-lives (whichever is longer) before clinic entry (Day -1), or plans to use an investigational drug (other than the study drug) during the study.
- •20. Subjects who have made any blood donation within 56 days of clinic entry (Day -1).
- •21. Subjects who have made any plasma donation within 7 days of clinic entry (Day -1).
- •22. Subjects who cannot understand or comply with the study procedures or whom the investigator suspects cannot understand or comply with the procedures.
研究者
相似试验
进行中（未招募）
1 期
A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis via the Expression of avb3 Integrin Receptors by [18F]AH111585 PET ImagingsarcomaEUCTR2008-005219-16-GBGE Healthcare Ltd30
已完成
2 期
A Phase 2a, Proof-of-Concept, Open-Label Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Obicetrapib in Patients with Early Alzheimer*s Disease (Hetero/Homozygote APOE4 Carriers)10057167dementiaAlzheimer's diseaseNL-OMON51159ewAmsterdam Pharma B.V.15
进行中（未招募）
1 期
A study to evaluate the effect and safety of obicetrapib in patients with early Alzheimer's disease (Hetero/Homozygote APOE4 carriers)Alzheimer's diseaseEUCTR2021-002687-41-NLewAmsterdam Pharma BV15
进行中（未招募）
1 期
Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients withXeroderma Pigmentosum (XP)EUCTR2019-000597-34-DECLINUVEL EUROPE LIMITED6
进行中（未招募）
1 期
Study to evaluate the safety and the efficacy of the photoprotective drug, afamelanotide in patients with Xeroderma Pigmentosum C and VPatients with Xeroderma Pigmentosum C and VEUCTR2021-001419-10-ESCLINUVEL EUROPE LIMITED6